



Founded in 1888 by Dr. Wallace C. Abbott, a Chicago physician, Abbott is a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritional products for children and adults, and medical products, including devices, diagnostic tests and instruments. Headquartered in north suburban Chicago, Abbott employs more than 72,000 people and markets its products worldwide.

- 2 Financial Highlights
- 5 Rankings
- 6 Pharmaceuticals
- 10 Nutritional Products
- 14 Medical Products
- 16 Medical Products – Laboratory Diagnostics
- 17 Medical Products – Diabetes Care
- 17 Medical Products – Molecular Diagnostics
- 18 Medical Products – Point of Care Diagnostics
- 18 Medical Products – Vascular Devices
- 19 Medical Products – Medical Optics
- 19 Medical Products – Animal Health
- 20 History
- 23 Global Citizenship
- 26 Five-Year Financial Summary
- 28 Plant Locations
- 28 Directors
- 29 Senior Management and Corporate Vice Presidents



Abbott is focused on advancing patient care by developing innovative solutions in pharmaceuticals, diagnostics, medical devices and nutritional products.



# Financial Highlights

In 2008, Abbott reported sales of \$29.5 billion, reflecting growth of 13.9 percent. The company's Pharmaceuticals business generated sales of approximately \$17 billion. The Nutritional Products business generated sales of nearly \$5 billion. The Medical Products business generated sales of more than \$7 billion. In addition, 2008 marked the 36th straight year Abbott's dividend has increased. Abbott has paid 340 consecutive quarterly dividends since 1924.

Abbott's leadership positions in several multi-billion-dollar businesses provide a unique balance of revenue, growth opportunities and cash flow sources that allow the company to invest in its future. In 2008, to further strengthen its business and sustain its success, Abbott invested approximately \$2.7 billion in research and development.



## Financial Highlights (cont.)

### R&D Investment

(dollars in billions)



### Cash Dividends Declared per Share

(dollars per share)



## Rankings

Abbott is ranked among the top companies in the world for financial strength and workplace excellence by leading national publications, including:

<b>Barron's</b>	Ranked 15th on <i>Barron's</i> "World's Most Respected Companies" list.
<b>BusinessWeek</b>	Named one of the "Best Places to Launch a Career."
<b>DiversityInc.</b>	Named one of the "Top 50 Companies for Diversity."
<b>Forbes</b>	Ranked 118th on the <i>Forbes Global 2000</i> list (ranked by 2008 sales, profits, assets and market value).
<b>Fortune</b>	Ranked 3rd among the "Most Admired Companies" in the pharmaceutical sector. Ranked 96th on the <i>Fortune 500</i> list of the largest U.S.-based corporations (ranked by 2007 revenue).
<b>Working Mother</b>	Named one of the "Top 10 Best Employers for Working Mothers."

# Pharmaceuticals

Abbott medicines are used to treat some of the world's most serious and prevalent diseases, including rheumatoid arthritis, psoriasis, Crohn's disease, lipid disorders, kidney disease and HIV. We also continue to pursue new therapeutic indications for existing medications that offer patients and physicians important treatment options.

## KEY FRANCHISES

---



Cardiovascular



Immunology



Virology



Metabolics



Renal Care

# Pharmaceuticals

Abbott is dedicated to discovering, developing and marketing important treatment options that improve patient health. Abbott sells pharmaceutical products in several therapeutic areas.

**Anesthesia.** Provides inhalation anesthetic agents, neuromuscular blockers, sedatives and other analgesic pain therapies.

*Ultane, Sevorane (sevoflurane)* Inhalation anesthetic for both inpatient and outpatient procedures, for adult and pediatric use.

**Anti-Infectives.** Antibiotics for the treatment of respiratory infections and skin infections.

*Biaxin, Klacid, Klaricid (clarithromycin), Biaxin XL, Klaricid OD (clarithromycin extended-release formulation)* Oral macrolide antibiotic for the treatment of upper and lower respiratory tract infections. Clarithromycin is also used for skin and skin structure infections, treatment and prevention of Mycobacterium avium complex (MAC) and eradication of the ulcer-causing bacterium H. pylori.

*Erythromycin, PCE* Generic and polymer-coated macrolide antibiotic.

**Cardiovascular.** Includes anti-hypertensive medicines for reducing high blood pressure, treating congestive heart failure and medicine for managing cholesterol abnormalities and triglycerides.

*Blopress, Tiadyl (candesartan)* Angiotensin-2 antagonist for hypertension. (Marketed outside the United States.)

*Niaspan (niacin extended-release tablets), Simcor (niacin extended-release/simvastatin), TriCor (fenofibrate tablets), Trilipix (fenofibric acid) delayed release* Used along with diet and exercise to raise HDL, or "good" cholesterol, lower LDL, or "bad" cholesterol, and lower triglycerides.

*Simdax (levosimendan)* Injectable for acute congestive heart failure. (Marketed outside the United States.)

**Immunology.** Medications used to treat some diseases of the immune system.

*Humira (adalimumab)* Self-injectable, TNF-blocking, monoclonal antibody for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, moderate to severe Crohn's disease, moderate to severe chronic plaque psoriasis and moderate to severe polyarticular juvenile idiopathic arthritis.

**Metabolics.** Includes medicines for the management of obesity and the treatment of thyroid disease.

*Meridia, Reductil (sibutramine hydrochloride monohydrate)* Serotonin and norepinephrine reuptake inhibitor (SNRI) used with a reduced-calorie diet for the management of obesity.

*Synthroid (levothyroxine sodium)* Synthetic thyroid hormone for the treatment of hypothyroidism and subclinical hypothyroidism.

**Neuroscience.** Medications to treat neurological conditions.

*Depakote ER (divalproex sodium extended-release tablets), Depakote, Epival, Valcote (divalproex sodium enteric-coated tablets)* Anti-epileptic agent (adult/pediatric) also used for the treatment of the manic episodes of bipolar disorder and for the prevention of migraine headaches (adult).

**Pediatric and Neonatal.** Medications for newborns with serious respiratory conditions.

*Survanta (beractant)* Lung surfactant used to treat and prevent respiratory distress syndrome (RDS) in premature newborns.

*Synagis (palivizumab)* Monoclonal antibody for the prevention of serious respiratory infection due to respiratory syncytial virus (RSV) infection in pediatric patients at high risk of RSV. (Marketed outside the United States.)

**Renal Care.** Includes oral and injectable activated vitamin D agents developed to treat patients with complications of chronic kidney disease.

*Zemplar (paricalcitol injection and capsules)* Therapy for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease.

**Urology and Reproductive Health.** Includes medicines for the palliative treatment of advanced prostate cancer, endometriosis, anemia associated with uterine fibroids and central precocious puberty.

*Lupron Depot, Lucrin (leuprolide acetate depot suspension)* Synthetic hormone for the treatment of advanced prostate cancer, endometriosis, preoperative treatment of anemia associated with uterine fibroid tumors in combination with iron and central precocious puberty.

**Virology.** Medications to treat HIV.

*Kaletra, Aluvia (lopinavir/ritonavir)* Protease inhibitor used in conjunction with other antiretroviral agents for the treatment of HIV.

*Norvir (ritonavir)* Protease inhibitor used in conjunction with other antiretroviral agents for the treatment of HIV.

# Nutritional Products

Abbott offers some of the world's most trusted brands of pediatric nutrition, adult nutrition, therapeutic nutrition, performance nutrition and nutritious snack products, including *Similac Advance EarlyShield*, *Gain Advance*, *PediaSure*, *Ensure*, *Glucerna* and *EAS* brands. We also provide specially formulated medical nutrition products for patients with unique dietary needs due to illness or injury.

## KEY FRANCHISES

---



Pediatric Nutrition



Adult Nutrition

# Nutritional Products

Abbott is a leader in providing trusted pediatric and adult nutrition formulas, shakes, bars, snacks and tube-feeding products to improve people's quality of life.

**Pediatric Nutrition.** Abbott develops products that support the growth and development of infants and children and makes these products available in innovative, consumer-friendly packaging. Specialty formulations include products for premature and low-birth-weight infants and products for infants and children with special tolerance or nutritional needs.

**Gain Advance** A nutritional supplement for children 6 months to 1 year old during the transition to solid foods. *Gain Advance* contains the *Eye-Q* system of nutrients, nucleotides and increased levels of protein and energy to support brain development, the immune system and overall growth. (Marketed outside the United States.)

**Gain Plus Advance** Nutritional choice for children 1 to 3 years old. The *Eye-Q* system is also available with *Gain Plus Advance*, and it contains pre- and probiotics (synbiotics) to help support children's natural defenses. (Marketed outside the United States.)

**Gain Kid, Gain School** Growth-focused nutritional supplements for children 3 years old and beyond, delivering more than 30 essential nutrients. *Gain Kid* is also available with the *Eye-Q* system of nutrients. (Marketed outside the United States.)

**NutriPals** A line of shakes for children that provide a good source of more than 20 essential vitamins and minerals plus protein in a take-along snack.

**PediaLyte** Oral electrolyte maintenance solution to help prevent dehydration by quickly replacing fluids and electrolytes lost during diarrhea and vomiting. Also available as *PediaLyte Freezer Pops* and *PediaLyte Singles*.

**PediaSure, PediaSure Complete** Complete, balanced nutritional formula in a variety of flavors for children 1 to 13 years old. Available with fiber, as an oral supplement and in a tube-feeding formulation. *PediaSure Complete* (marketed outside the United States) contains synbiotics.

**Similac Advance** A complete line of infant and toddler formulas that offer DHA, ARA and a patented blend of nucleotides to help support healthy development of the eyes, brain and immune system. The line also includes highly specialized products to meet the unique needs of premature and low-birth-weight babies, including *Similac Human Milk Fortifier*, *Similac Special Care* and *Similac NeoSure*.

**Similac Advance EarlyShield** Infant formula with a blend of prebiotics, nucleotides and antioxidants to support a baby's natural immune system. Utilizes a new, redesigned *SimplePac* package that has a one-hand grip and a hinged lid with a secure scoop.

**Similac Alimentum** A formula for infants with food allergies or colic due to protein sensitivity.

**Similac Isomil Advance** A broad line of soy-based formulas for infants and toddlers with common feeding problems such as fussiness, gassiness and spitting up.

**Similac Organic** The first major brand-name organic infant formula that is certified USDA Organic and has the trusted nutritional benefits of *Similac Advance* baby formula with the wholesomeness of organic milk.

**Similac Sensitive, Similac Sensitive RS** Lactose-free infant formulas indicated for mild gastrointestinal intolerance symptoms.

**Adult Nutrition.** Abbott offers a broad selection of nutrition bars, shakes and related products that satisfy a wide range of consumer nutrition needs.

**EAS** A leading brand of sports nutrition bars, shakes and dietary supplements designed to help active-lifestyle consumers meet their fitness, performance and endurance goals.

**Ensure** A broad line of leading adult nutritional products, providing a source of complete, balanced nutrition to help consumers stay active, healthy and energetic. *Ensure* shakes are available in a variety of flavors and nutritional formulations.

**ZonePerfect** A leading brand of convenient nutritional bars designed to satisfy hunger through a unique balance of carbohydrates, protein and fat.

**Therapeutic Nutrition.** Abbott offers medical nutritionals and devices for patients with special dietary needs who require tube feeding or other nutritional interventions due to complex illness or injury. Abbott also offers specialized nutrition products for infants and children with multiple food allergies, severe gastrointestinal impairment or metabolic diseases.

**Companion, EnteraLite Infinity, Patrol, Quantum** Complete line of enteral feeding pumps, tubes and devices.

**EleCare** Nutritional formula for infants and children with multiple food allergies or severe gastrointestinal impairment.

**Glucerna, Glucerna SR** The first therapeutic nutritional product for people with diabetes or patients with impaired glucose tolerance. Available in shakes, meal bars, cereal, snack bars and tube-feeding formulations. *Glucerna SR* (marketed outside the United States) is an advanced formulation to improve glycemic control and help people with diabetes achieve or maintain optimal weight management.

**Jevity** Fiber-fortified liquid formula line available with various protein and caloric levels for both short- and long-term tube feeding.

**Juven** Therapeutic nutrition drink mix to help patients build lean body mass and support wound healing.

**Nepro, Suplema** Specialized nutritional products for people with kidney disease.

**Oxepa, Pulmocare** Specialized nutritional products for patients with respiratory conditions, including acute lung injury/acute respiratory distress syndrome (*Oxepa*) and pulmonary disease (*Pulmocare*).

**ProSure** A clinically tested therapeutic nutritional product, specially designed to help people with cancer-induced weight loss to gain weight and strength and improve their quality of life. (Marketed outside the United States.)

**Vital Jr.** Specialized nutrition for children with malabsorption, maldigestion and other GI conditions to help them maintain normal growth and development.

# Medical Products

Abbott drives innovation in the fast-paced medical technology market. Our medical products are advancing disease diagnosis, vision care, diabetes management and the treatment of vascular disease.

## KEY FRANCHISES

---



Laboratory  
Diagnostics




Molecular  
Diagnostics



Medical  
Optics



Diabetes  
Care



Vascular  
Devices

---

## Medical Products – Laboratory Diagnostics

Abbott Laboratory Diagnostics offers a broad range of innovative instruments and tests across key segments in the global diagnostics market, including hospitals, reference laboratories, blood banks, physician offices and clinics.

**Immunoassay and Clinical Chemistry.** Includes systems and assays to measure a variety of analytes found in the blood and to diagnose and monitor diseases and therapies. Also includes blood-screening instrumentation and assays used to ensure the safety of the blood supply.

**AbbottLink** Software that transmits instrument performance information to Abbott's service operations through the Internet, enhancing the remote identification and rapid resolution of technical issues on select analyzers.

**ABBOTT PRISM** Fully automated analyzer specifically designed for high-volume blood centers and blood banks to screen donated blood for multiple viral assays. Menu includes chagas disease, HIV, hepatitis and HTLV assays. (Not all assays are available in the United States.)

**ACCELERATOR Automated Processing Systems** Automates the labor-intensive sample identification, routing, centrifugation and storage logistics in the laboratory. *ACCELERATOR APS* improves process consistency, reduces dependency on manual labor and enhances overall operator safety.

**ARCHITECT c8000, c16000** High- and medium-volume clinical chemistry analyzers with broad testing menus to facilitate routine and specialty testing.

**ARCHITECT ci8200, ci16200** Analyzers that integrate the *ARCHITECT* clinical chemistry analyzers and the *i2000sr* to provide a consolidated workstation to perform both clinical chemistry and immunoassay testing.

**ARCHITECT i2000, i2000sr, i1000sr** Modular analyzers that provide immunoassay testing. Menu includes tests for cancer, cardiovascular and thyroid disease, fertility and pregnancy.

**AxSYM, AxSYM Plus** Automated immunoassay analyzer with continuous access and STAT capabilities. Menu includes tests for cancer, cardiovascular and thyroid disease, drugs of abuse, fertility, hepatitis and pregnancy.

**IMx** Automated benchtop analyzer for immunoassay testing. Menu includes tests for cardiovascular and thyroid disease, cancer and fertility.

**Instrument Manager** Software that provides connectivity and functionality across the entire laboratory, reducing turnaround time and labor dependency, while improving the quality of results.

**TDx and TDxFLx** Automated benchtop analyzers for monitoring therapeutic drug levels. Menu includes theophylline, vancomycin, drugs of abuse and thyroid tests.

**Hematology.** Abbott develops, manufactures and markets *CELL-DYN* hematology systems used to perform sophisticated blood cell analysis.

**CELL-DYN Ruby, 3700, 3200, 1800** Complete line of highly automated hematology analyzers to meet the testing needs of any laboratory, whether high or low volume.

**CELL-DYN Emerald** Low-volume, automated hematology analyzer for small to midsize clinical laboratories.

**CELL-DYN Sapphire** High-volume, automated hematology analyzer that incorporates monoclonal antibody tests, reducing the need for external sample analysis.

## Medical Products – Diabetes Care

Abbott Diabetes Care is committed to improving the lives of people with diabetes by providing innovative glucose monitoring systems that offer patients and/or health care professionals fast, convenient and accurate results.

**FreeStyle Freedom Lite blood glucose monitoring system** Easy-to-hold, easy-to-read blood glucose monitoring system that uses a 0.3 microliter blood sample, has the most approved alternative sites for testing, features a 5-second average test time and requires no coding for easy testing.

**FreeStyle Lite blood glucose monitoring system** Small, discreet blood glucose monitoring system that offers key features such as no coding, the world's smallest blood sample size, a backlight and a test strip port light.

**FreeStyle Navigator continuous glucose monitoring system** Accurately measures and provides minute-by-minute glucose trend updates using a 5-day sensor, worn on the back of the upper arm or on the abdomen, that wirelessly transmits readings to a receiver, pagerlike device.

**Precision Xceed Pro** A portable whole-blood testing system that may be used to test glucose and  $\beta$ -Ketone in healthcare settings.

**Precision Xtra advanced diabetes monitoring system** The only leading system on the market among leading brands with the technology to test blood glucose and ketone levels with the same meter and test strips.

## Medical Products – Molecular Diagnostics

Abbott Molecular offers innovative tests and instruments for the early detection of pathogens and genomic and chromosomal changes, allowing for earlier diagnosis, selection of appropriate therapies and monitoring disease progression.

**Abbott m2000** Automated system integrates sample preparation and extraction with real-time polymerase chain reaction (PCR) amplification and detection technology. Menu includes tests for HIV-1, HBV, HCV, HPV and CT/NG. (Not all tests are available in the United States.)

**Abbott RealTime tests for HIV-1, HCV, HBV, HPV and CT/NG** Molecular tests for use on the *m2000* automated system, based on real-time PCR (polymerase chain reaction) technology. The tests are used to monitor hepatitis and HIV-1 viral loads and to diagnose chlamydia and gonorrhea infections, and human papillomavirus. (Not all tests are available in the United States.)

**DNA Fluorescent in-situ Hybridization (FISH) Probe Technology** Genomic tests for chromosomal changes associated with congenital disorders and cancer, including probes to detect the HER-2 gene in breast cancer patients and probes that aid in the initial diagnosis of bladder cancer in patients with hematuria or to monitor the recurrence of bladder cancer.

**Ibis T5000 Biosensor System** System designed for the rapid identification of bacteria, viruses, and fungi and to provide information about strain type, virulence, and drug resistance. Currently intended for research use only.

**PathVysion HER-2 DNA Probe Kit** Detects the HER-2 gene in breast cancer patients. Patients who have extra copies of this gene are candidates for treatment with Herceptin, a targeted monoclonal treatment.

**UroVysion** DNA-based test for the initial diagnosis of patients with bladder cancer presenting with hematuria (blood in urine) or suspected of having bladder cancer, and the monitoring of bladder cancer recurrence. Detects genetic changes in bladder cells.

**ViroSeq HIV-1** Genotyping system that is used as an aid in monitoring and treating HIV infection. Detects HIV-1 mutations associated with drug resistance.

## Medical Products – Point of Care Diagnostics

Abbott Point of Care Diagnostics develops, manufactures and markets critical medical diagnostic and data management products for rapid blood analysis.

<i>i-STAT System</i>	<i>i-STAT</i> technology provides physicians with the information they need to make lifesaving decisions in the intensive and acute care settings of the hospital. The <i>i-STAT System</i> offers a broad menu of tests for diagnostic and treatment indicators related to disease state management and clinical practice guidelines to support a patient-centric approach to health care.
----------------------	---

## Medical Products – Vascular Devices

Abbott Vascular Devices markets a broad portfolio of coronary, endovascular and vessel closure technologies used in the treatment of vascular disease.

### Coronary

<i>ASAHI guide wires</i>	Full product line of guide wires that facilitate access to diseased vessels and allow the clinician to thread interventional devices to the most difficult-to-reach areas of the vasculature.
--------------------------	---

<i>HI-TORQUE guide wires</i>	Full line of coronary guide wires to assist the interventional cardiologist in accessing treatment areas.
------------------------------	---

<i>MULTI-LINK VISION, MULTI-LINK MINI VISION stents</i>	Thin-strut metallic stents based on cobalt chromium technology for coronary obstructions. <i>MULTI-LINK MINI VISION</i> is for use in small vessels (2.0 mm to 2.5 mm), and <i>MULTI-LINK VISION</i> is for use in vessels 3.0 mm to 4.0 mm.
---	--

<i>VOYAGER balloons</i>	Line of coronary balloons enabling the potential for superb stent expansion in the arteries surrounding the heart. Includes <i>VOYAGER NC</i> , a high-pressure balloon dilatation catheter for use in both predilatation and postdilatation procedures.
-------------------------	--

<i>XIENCE V stent system</i>	Drug-eluting coronary stent system developed on the <i>MULTI-LINK VISION</i> platform. The <i>XIENCE V</i> stent system combines the cobalt chromium stent with everolimus to treat coronary obstructions and improve vessel narrowing in patients with symptomatic heart disease.
------------------------------	--

### Endovascular

<i>Acculink, AccUNET</i>	The <i>Acculink</i> carotid stent is a conformable self-expanding nitinol stent designed for use in the carotid arteries of the neck that carry blood to the brain. It is used with the <i>AccUNET</i> embolic protection system, a filter to capture plaque fragments (emboli) that may be dislodged during carotid stenting procedures.
--------------------------	---

<i>Fox Balloons</i>	Line of peripheral balloons for endovascular procedures designed for optimal crossing and deliverability of small and large vessels. Includes <i>Fox Cross</i> , <i>Fox Plus</i> and <i>Fox sv</i> .
---------------------	--

<i>Xact, Emboshield</i>	<i>Xact</i> is a self-expanding stent designed specifically for use in the carotid arteries of the neck that carry blood to the brain. <i>Emboshield</i> is a filter used to capture plaque fragments (emboli) that may be dislodged during carotid stenting procedures.
-------------------------	--

### Vessel Closure

<i>Perclose ProGlide, Perclose ProStar</i>	Suture-mediated vessel closure devices designed to expedite recovery following diagnostic or interventional catheterization procedures.
--	---

<i>StarClose SE</i>	Vascular closure device that features a flexible nitinol clip to enable secure extravascular closure of the femoral artery access site in diagnostic or interventional catheterization procedures.
---------------------	--

## Medical Products – Medical Optics

Abbott Medical Optics provides market-leading technologies to address a wide range of vision disorders.

### Cataract Products

<i>Healon Viscoelastics</i>	Family of viscoelastics that satisfies a range of surgical needs.
-----------------------------	---

<i>ReZoom Multifocal IOL</i>	Refractive intraocular lens (IOL) that uses optical zones to provide near, intermediate and distance vision, reducing the need for eyeglasses.
------------------------------	--

<i>Tecnis IOL</i>	Monofocal, aspheric IOL designed to improve functional vision.
-------------------	--

<i>Tecnis Multifocal IOL</i>	Diffraction, aspheric IOL that provides near, intermediate and distance vision with high spectacle independence.
------------------------------	--

<i>WhiteStar Signature Phacoemulsification System</i>	Ultrasonic device that emulsifies and extracts a hard, cloudy lens using less heat and turbulence and fusion fluidics to optimize outcomes.
---	---

### Corneal Products

<i>Blink Contacts Lubricating Eye Drops</i>	Designed to provide contact lens wearers prolonged lubrication and protection against dryness.
---	--

<i>Blink Tears Lubricating Eye Drops</i>	Designed to provide relief to dry-eyed patients.
--	--

<i>COMPLETE Multi-Purpose Solution Easy Rub Formula</i>	Single-bottle solution formulated to effectively clean and disinfect contact lenses.
---	--

<i>Oxysept UltraCare Formula: Peroxide Disinfection System</i>	Hydrogen peroxide system that provides powerful disinfection efficacy for contact lenses.
--	---

### Refractive Products

<i>Advanced CustomVue Procedure</i>	Custom LASIK procedure that corrects unique imperfections in each patient's eyes and is capable of treating the industry's broadest range of refractive conditions.
-------------------------------------	---

<i>IntraLase FS Laser</i>	Ultrafast laser that focuses pulses of light below the surface of the cornea to create the flap before a LASIK treatment is performed.
---------------------------	--

<i>STAR S4 IR Excimer Laser System</i>	Computer-driven excimer laser that corrects refractive errors by reshaping the cornea.
--	--

<i>WaveScan WaveFront System</i>	Diagnostic device that captures unique imperfections in each patient's eyes and creates a personalized treatment plan.
----------------------------------	--

## Medical Products – Animal Health

Abbott Animal Health is a leader in perioperative health care for the veterinary market. Products include anesthetic and wound care products, nutritionals, a complete line of IV fluid therapy and other veterinary critical care products.

<i>AlphaTRAK blood glucose monitoring system</i>	Blood glucose monitoring system specifically calibrated and validated for dogs and cats that provides veterinarians fast, inexpensive, convenient and accurate blood glucose results.
--	---

<i>Fluid Therapy</i>	Complete line of IV fluids, sets, catheters and accessories that provide venous access, keep organs properly perfused and help maintain blood pressure.
----------------------	---

<i>GLUture Topical Tissue Adhesive</i>	Medical-grade adhesive indicated for wound closure.
--	---

<i>SevoFlo (sevoflurane)</i>	Inhalant anesthetic that provides veterinarians rapid induction of anesthesia and excellent control during the maintenance phase of anesthesia.
------------------------------	---

### A tradition of innovation.

For more than 120 years, Abbott has been a pioneer in developing innovative solutions that improve health and the practice of health care. In 1888, 30-year-old Wallace C. Abbott, M.D., began making a new form of medicine. Using the active – or alkaloid – part of a medicinal plant, he formed tiny pills, called “dosimetric granules,” which provided a measured amount of the drug. The demand for these accurate granules soon far exceeded the needs of his own practice. From a small operation based above Dr. Abbott’s pharmacy, Abbott has evolved into one of the world’s leading health care companies.

1888	Dr. Abbott begins producing dosimetric granules in his apartment on Chicago’s North Side.
1900	The business is officially incorporated in Illinois as the Abbott Alkaloidal Company.
1915	The company changes its name to Abbott Laboratories.
1920	Dr. Abbott breaks ground for a new manufacturing facility in North Chicago, Ill.
1929	Abbott stock is listed on the Chicago Stock Exchange. The offering is 20,000 shares for \$32 each.
1931	Abbott establishes its first international affiliate in Montreal, Canada. The company’s international presence will grow steadily.
1936	Abbott introduces the anesthetic agent Pentothal, developed by Abbott scientists Drs. Ernest Volwiler and Donalee Tabern. For this discovery, they are named to the U.S. Inventors Hall of Fame in 1986.
1941	Abbott is one of the five pioneers in the United States to start commercial production of penicillin.
1952	Erythrocin, a new antibiotic with good activity against gram-positive bacteria, is introduced.
1962	Abbott enters a joint venture with Dainippon Pharmaceutical Co., Ltd., of Osaka, Japan, to manufacture radiopharmaceuticals. Major plant expansions are completed in England, Italy and France.
1964	The company acquires M&R Dietetic Laboratories of Columbus, Ohio, which eventually becomes Abbott’s Ross Products Division.
1965	Abbott moves major operations to Abbott Park, a 420-acre site southwest of its North Chicago headquarters.

1973	Abbott forms its diagnostics division to bring together all diagnostic products and services. The company also introduces <i>Ensure</i> , the first adult medical nutritional.
1977	TAP Pharmaceuticals is formed as a joint venture between Abbott and Takeda Chemical Industries, Ltd., of Japan.
1983	<i>Depakote</i> , a new treatment for epilepsy, is approved in the United States.
1985	Abbott wins U.S. approval to market the world’s first diagnostic test for AIDS. TAP receives approval for <i>Lupron</i> , a new therapy for prostate cancer.
1987	<i>Hytrin</i> , a new cardiovascular drug for the treatment of hypertension, receives Food and Drug Administration (FDA) approval.
1988	Abbott celebrates its centennial. The <i>IMx</i> immunoassay system is introduced and goes on to become one of the best-selling new products in Abbott’s history.
1990	<i>Biaxin</i> , an important new macrolide antibiotic, is introduced.
1991	Several major products are introduced worldwide, including <i>Survanta</i> , for the treatment of neonatal respiratory distress syndrome. Abbott enters the hematology testing market with the acquisition of Sequoia-Turner Corp.
1993	<i>Hytrin</i> receives FDA clearance for use in treating symptoms of benign prostatic hyperplasia, a condition of the prostate. Abbott launches <i>AxSYM</i> , a new, labor-saving diagnostic system.
1994	Abbott introduces sevoflurane, the first truly universal anesthetic, and completes an agreement to cross-license LCR and PCR, two gene amplification technologies.
1995	TAP receives approval for <i>Prevacid</i> , a proton pump inhibitor used in treating ulcers. <i>ABBOTT PRISM</i> , the first fully automated, high-volume blood analyzer, is introduced outside the United States.
1996	The company receives FDA approval for <i>Norvir</i> , a protease inhibitor for the treatment of HIV and AIDS. The company enters the glucose testing market with its acquisition of MediSense, Inc.
1997	Abbott acquires the parenteral products business of Sanofi Pharmaceuticals, Inc., and also launches several new products in the United States, including an improved version of <i>Similac</i> infant formula.
1998	Abbott launches <i>Glucerna</i> shakes and snack bars, specially formulated nutritionals for people with diabetes. <i>Depakote</i> surpasses lithium as the most-prescribed drug for treating mania. Abbott launches several pharmaceutical products, including <i>Zemlar</i> , <i>TriCor</i> and <i>Synagis</i> .
1999	Abbott launches <i>ARCHITECT</i> , a next-generation diagnostic system, and acquires Perclose, Inc., a leading vascular closure devices company.

- 2000** Abbott receives FDA approval for several new drugs or new formulations, including *Kaletra* (an advanced-generation protease inhibitor for the treatment of HIV/AIDS), *Biaxin XL* (a once-daily version of its flagship antibiotic) and *Depakote ER* (for migraine prevention).
- 2001** Abbott completes the acquisition of the pharmaceutical business of BASF, including the global operations of Knoll Pharmaceuticals. In addition, Abbott acquires Vysis, Inc., a leading genomic disease management company.
- 2002** Abbott receives FDA approval for *Humira* (for rheumatoid arthritis) and *Synthroid* (for hypothyroidism). The company launches *Similac Advance*, *Isomil Advance* and *NeoSure Advance* infant formulas in the United States. Abbott acquires the cardiovascular stent business of Biocompatibles International plc.
- 2003** Abbott launches three new immunodiagnosics systems on the *ARCHITECT* platform. Abbott receives European regulatory approval for *Humira* to treat rheumatoid arthritis. Abbott acquires JOMED's coronary and peripheral intervention business lines, ZonePerfect Nutritional Co. and Integrated Vascular Systems Inc.
- 2004** Abbott acquires TheraSense Inc., a leading blood glucose monitoring business, as well as i-STAT Corp. and EAS Inc. Abbott creates Hospira, an independent, publicly traded company. Hospira is one of the largest global specialty pharmaceutical and medication delivery companies serving the hospital market.
- 2005** Abbott introduces several medical devices, including the *Xact/Emboshield* carotid stent system, *StarClose* vascular closure device and, in the United States, diagnostic devices *ABBOTT PRISM* and *CELL-DYN Sapphire*. Abbott also receives FDA approval for two new indications for *Humira* (psoriatic arthritis and early rheumatoid arthritis).
- 2006** Abbott acquires the vascular business of Guidant Inc., a leader in coronary and vascular products, and Kos Pharmaceuticals, a specialty pharmaceutical company with a significant cholesterol management portfolio. Abbott also launches its *XIENCE V* drug-eluting stent outside the United States.
- 2007** Abbott submits a record number of major products for regulatory approval and launches *Humira* for Crohn's disease and *Niaspan* to treat cholesterol and triglycerides.
- 2008** Abbott receives nine major regulatory approvals, including three indications for *Humira*, *Simcor*, *ARCHITECT i1000SR*, *FreeStyle Navigator* continuous glucose monitoring system, *FreeStyle Freedom Lite*, *XIENCE V* and *Trilipix*. Abbott also concludes its TAP joint venture.
- 2009** Abbott acquires Ibis Biosciences. Abbott also acquires Advanced Medical Optics (AMO), a leader in the growing vision care market.

# Global Citizenship

Good corporate citizenship is integral to Abbott's mission as a global health care company. We are committed to doing business in a responsible and sustainable way that brings wide-ranging benefits — health, social, economic — to the communities where we live and work.

Citizenship influences all aspects of Abbott — how we advance business objectives, engage stakeholders, implement policies, apply social investment and philanthropy, and exercise influence to make a productive contribution to society.

Each year, we continue to improve our corporate citizenship, and 2008 marked the fourth straight year in which Abbott was named to the Dow Jones Sustainability World and North America indices. These indices are the leading benchmarks of best-in-class economic and social performance of global companies. The following is a brief summary of our ongoing global citizenship efforts:



## Global Citizenship (cont.)

### **Innovating for the future**

Abbott is using its expertise in science, technology and health to address important areas where we can make a difference. Our commitment to innovation is evident in Abbott's research and development activities, where we invested \$2.7 billion during 2008. Innovation is equally important in every other aspect of our business — from devising better manufacturing processes, to improving the effectiveness and reach of our marketing and educational programs, to the distribution of our products and the general conduct of our organization.

### **Improving access**

Developing effective health care products is only part of our goal. We must also work to ensure that those in need get access to them. We are dedicated to improving access to our medicines and our other health care products through Abbott's own programs and by partnering with others who can help. In 2008, our contributions totaled more than \$460 million, and more than 155,000 patients were helped by assistance programs offered or supported by Abbott. Through these programs, Abbott provided products valued at more than \$255 million.

### **Protecting patients and consumers**

We work diligently to ensure the quality of our products and the health and safety of those who use and come into contact with them. As part of this process, we not only work to protect the patient, but also the health and safety of our employees and the communities where we live and work.

### **Safeguarding the environment**

Abbott is committed to helping address the global challenges of climate change and water scarcity and to minimizing the environmental impacts of our products, our manufacturing and all other aspects of our business. In 2008, we achieved significant improvement in the eco-efficiency of our manufacturing sites. We reduced our greenhouse gas emissions by 3 percent and our water usage by 4 percent from our 2007 levels.

For more details on our citizenship efforts, download the report at [www.abbott.com/citizenship](http://www.abbott.com/citizenship).

---

Through financial and product donations, Abbott and the Abbott Fund support the work of the Infant Welfare Society of Chicago to provide primary health care for low-income, uninsured women and children. Approximately 10,000 women and children receive care annually at the clinic.

# Five-Year Financial Summary (a)

(dollars in millions, except per share data)

Year Ended December 31	2008	2007	2006	2005	2004
<b>Summary of Operations:</b>					
Net sales	\$29,527.6	25,914.2	22,476.3	22,337.8	19,680.0
Cost of products sold	\$12,612.0	11,422.0	9,815.1	10,641.1	8,884.2
Research and development (a)	\$ 2,688.1	2,505.6	2,255.3	1,821.2	1,696.8
Selling, general and administrative	\$ 8,435.6	7,408.0	6,349.7	5,496.1	4,921.8
Operating earnings	\$ 5,693.8	4,578.5	2,042.2	4,362.3	3,898.3
Interest expense	\$ 528.5	593.1	416.2	241.4	200.2
Interest income	\$ (201.2)	(136.8)	(123.8)	(87.7)	(51.1)
Other (income), net	\$ (489.7)	(347.5)	(526.5)	(411.3)	(376.4)
Earnings from continuing operations before taxes	\$ 5,856.3	4,469.6	2,276.4	4,619.9	4,125.6
Taxes on earnings from continuing operations	\$ 1,122.1	863.3	559.6	1,247.9	949.8
Earnings from continuing operations	\$ 4,734.2	3,606.3	1,716.8	3,372.1	3,175.8
Basic earnings per share from continuing operations	\$ 3.06	2.34	1.12	2.17	2.03
Diluted earnings per share from continuing operations	\$ 3.03	2.31	1.12	2.16	2.02
<b>Financial Position:</b>					
Working capital	\$ 5,106.8	4,939.5	(669.3)	3,970.5	3,908.8
Long-term investments	\$ 1,073.7	1,125.3	1,229.9	134.0	145.8
Net property and equipment	\$ 7,219.2	7,518.1	6,946.4	6,003.1	6,007.9
Total assets	\$42,419.2	39,713.9	36,178.2	29,141.2	28,767.5
Long-term debt	\$ 8,713.3	9,487.8	7,009.7	4,571.5	4,787.9
Shareholders' investment	\$17,479.6	17,778.5	14,054.2	14,415.3	14,325.8
Return on shareholders' investment from continuing operations	% 26.9	22.7	12.1	23.5	23.8
Book value per share	\$ 11.26	11.47	9.14	9.37	9.18
<b>Other Statistics:</b>					
Gross profit margin	% 57.3	55.9	56.3	52.4	54.9
Research and development to net sales	% 9.1	9.7	10.0	8.2	8.6
Net cash from operating activities of continuing operations	\$ 6,994.6	5,183.8	5,262.1	5,047.4	4,306.0
Capital expenditures	\$ 1,287.7	1,656.2	1,337.8	1,207.5	1,291.6
Cash dividends declared per common share	\$ 1.44	1.30	1.18	1.10	1.04
Common shares outstanding (in thousands)	1,552,433	1,549,910	1,537,243	1,539,235	1,560,024
Number of common shareholders	69,733	73,176	77,727	82,237	88,582
Number of employees	68,838	68,697	66,663	59,735	60,617
Sales per employee (in dollars)	\$ 428,943	377,225	337,163	373,948	324,662
Market price per share – high	\$ 61.09	59.50	49.87	50.00	47.63
Market price per share – low	\$ 45.75	48.75	39.18	37.50	38.26
Market price per share – close	\$ 53.37	56.15	48.71	39.43	46.65

(a) In 2006, 2005 and 2004, Abbott also recorded pretax charges of \$2,014, \$17 and \$279, respectively, for acquired in-process research and development related to business acquisitions.

## Plant Locations

Abbott's corporate offices are located at 100 Abbott Park Road, Abbott Park, Illinois 60064-6400. The locations of Abbott's principal plants, as of December 31, 2008, are listed below.

Abbott Park, Illinois	Katsuyama, Japan
Alameda, California*	Longford, Ireland
Altavista, Virginia	Ludwigshafen, Germany
Barceloneta, Puerto Rico	North Chicago, Illinois
Brockville, Canada	Ottawa, Ontario, Canada*
Buenos Aires, Argentina	Redwood City, California*
Campoverde di Aprilia, Italy	Rio de Janeiro, Brazil
Casa Grande, Arizona	Santa Clara, California
Clonmel, Ireland	Singapore
Columbus, Ohio	Sligo, Ireland
Cootehill, Ireland	South Pasadena, California
Dartford, England*	Sturgis, Michigan
Des Plaines, Illinois	Temecula, California
Edison, New Jersey*	Wiesbaden, Delkenheim, Germany
Fairfield, California*	Witney, Oxon, England
Granada, Spain	Worcester, Massachusetts
Irving, Texas	Zwolle, the Netherlands
Jayuya, Puerto Rico	
Karachi, Pakistan	*Leased property

## Directors

Robert J. Alpern, M.D. <i>Dean, Yale School of Medicine New Haven, Conn.</i>	W. Ann Reynolds, Ph.D. <i>Former President, The University of Alabama at Birmingham Birmingham, Ala.</i>
Roxanne S. Austin <i>President, Austin Investment Advisors Newport Coast, Calif.</i>	Roy S. Roberts <i>Managing Director, Reliant Equity Investors LLC Chicago, Ill.</i>
William M. Daley <i>Head of the Office of Corporate Social Responsibility and Chairman of the Midwest, JPMorgan Chase &amp; Co. Chicago, Ill.</i>	Samuel C. Scott, III <i>Chairman, President and Chief Executive Officer, Corn Products International Inc. Westchester, Ill.</i>
W. James Farrell <i>Retired Chairman and Chief Executive Officer, Illinois Tool Works, Inc. Glenview, Ill.</i>	William D. Smithburg <i>Retired Chairman, President and Chief Executive Officer, The Quaker Oats Co. Chicago, Ill.</i>
H. Laurance Fuller <i>Retired Co-Chairman of the Board, BP Amoco, p.l.c. London, United Kingdom</i>	Glenn F. Tilton <i>Chairman, President and Chief Executive Officer, UAL Corporation and United Airlines, Inc., a wholly owned subsidiary of UAL Corporation Chicago, Ill.</i>
William A. Osborn <i>Chairman and former Chief Executive Officer, Northern Trust Corporation and its principal subsidiary, The Northern Trust Co. Chicago, Ill.</i>	Miles D. White <i>Chairman of the Board and Chief Executive Officer, Abbott</i>
The Rt. Hon. Lord Owen, CH <i>Chairman of Europe Steel, Ltd. London, United Kingdom</i>	

## Senior Management

Miles D. White* <i>Chairman of the Board and Chief Executive Officer</i>	James L. Tyree* <i>Executive Vice President, Pharmaceutical Products</i>	John M. Leonard, M.D. <i>Senior Vice President, Pharmaceuticals, Research and Development</i>
Thomas C. Freyman* <i>Executive Vice President, Finance and Chief Financial Officer</i>	Olivier Bohuon* <i>Senior Vice President, International Pharmaceuticals</i>	Heather L. Mason* <i>Senior Vice President, Diabetes Care</i>
Richard W. Ashley* <i>Executive Vice President, Corporate Development</i>	Thomas F. Chen* <i>Senior Vice President, International Nutrition</i>	James V. Mazzo* <i>Senior Vice President, Medical Optics</i>
John M. Capek, Ph.D.* <i>Executive Vice President, Medical Devices</i>	Stephen R. Fussell* <i>Senior Vice President, Human Resources</i>	Donald V. Patton, Jr.* <i>Senior Vice President, U.S. Nutrition</i>
Holger A. Liepmann* <i>Executive Vice President, Nutritional Products</i>	Robert B. Hance* <i>Senior Vice President, Vascular</i>	Mary T. Szela* <i>Senior Vice President, U.S. Pharmaceuticals</i>
Edward L. Michael* <i>Executive Vice President, Diagnostics Products</i>	John C. Landgraf* <i>Senior Vice President, Pharmaceuticals, Manufacturing and Supply</i>	Michael J. Warmuth* <i>Senior Vice President, Diagnostics</i>
Laura J. Schumacher* <i>Executive Vice President, General Counsel and Secretary</i>		

## Corporate Vice Presidents

Carlos Alban <i>Vice President, Pharmaceuticals, Western Europe and Canada</i>	John F. Ginascol <i>Vice President, Supply Chain, Nutrition</i>	D. Stafford O'Kelly <i>Vice President, Molecular Diagnostics</i>
Greg E. Arnsdorff <i>Vice President, Point of Care Diagnostics</i>	Honey Lynn Goldberg <i>Vice President, Associate General Counsel, Corporate Transactions</i>	Ramachandran Rajamanickam <i>Vice President, Nutrition, Pacific, Asia and Africa</i>
Catherine V. Babington <i>Vice President, Public Affairs</i>	Cecilia L. Kimberlin, Ph.D. <i>Vice President, Quality, Medical Products</i>	John R. Schilling, M.D. <i>Vice President, Sales and Marketing, U.S. Pharmaceutical Operations</i>
Michael G. Beatrice, Ph.D. <i>Vice President, Corporate Regulatory and Quality Science</i>	Zahir A. Lavji <i>Vice President, Pharmaceuticals, International Marketing</i>	AJ J. Shoultz <i>Vice President, Taxes</i>
Brian J. Blaser <i>Vice President, Diagnostics Operations</i>	Elaine R. Leavenworth <i>Vice President, Government Affairs</i>	Preston T. Simons <i>Vice President, Information Technology</i>
William J. Chase <i>Vice President, Treasurer</i>	Steven J. Lichter <i>Vice President, Pharmaceuticals, Manufacturing</i>	James P. Sullivan, Ph.D. <i>Vice President, Pharmaceuticals Discovery</i>
Jaime Contreras <i>Vice President, International Diagnostics</i>	Greg W. Linder* <i>Vice President, Controller</i>	Eugene Sun, M.D. <i>Vice President, Pharmaceuticals Clinical Development</i>
Thomas J. Dee <i>Vice President, Controller, International Pharmaceuticals</i>	Santiago Luque <i>Vice President, Pharmaceuticals, Latin America</i>	John B. Thomas <i>Vice President, Investor Relations</i>
Charles D. Foltz <i>Vice President, Vascular Products Operations</i>	Sean E. Murphy <i>Vice President, Licensing/ New Business Development</i>	Glenn S. Warner <i>Vice President, Pharmaceuticals, Japan</i>
Robert B. Ford <i>Vice President, Diabetes Care, Commercial Operations</i>	Corlis D. Murray <i>Vice President, Corporate Engineering Services</i>	Susan M. Widner <i>Vice President, Corporate Marketing</i>
Robert E. Funck <i>Vice President, Internal Audit</i>		*Denotes executive officer

Published by Abbott Investor Relations  
Investor Newsline: (847) 937-7300

The ticker symbol for Abbott's common stock is ABT. The principal market for Abbott's common shares is the New York Stock Exchange. Shares are also listed on the Chicago Stock Exchange and traded on various regional and electronic exchanges. Outside the United States, Abbott's shares are listed on the London Stock Exchange and the Swiss Stock Exchange.

**On the cover:** *PediaSure* – Mariana Pinto, Rio de Janeiro, Brazil

Five-year-old Mariana Pinto spends hours playing. In order to keep her energy up, she relies on *PediaSure* formula, a complete, balanced source of nutrition, providing the extra calories, plus the protein, vitamins and minerals needed for healthy growth. *PediaSure* products come in a variety of "kid approved" flavors.

Abbott trademarks and products in-licensed by Abbott are shown in italics in the text of this Fact Book.

Herceptin is not a trademark of Abbott Laboratories.

Not all products listed are approved in all countries.

©2009, Abbott Laboratories 120M/4/08

